Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.30 (
PARP
)
13,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor protein D52-like 2
(
TPD52L2
) and its family members form homo- and hetero-meric complexes essential for cell proliferation in multiple human cancers.
TPD52L2
is involved in cell migration and attachment in oral squamous cell carcinoma (OSCC). To confirm the role of
TPD52L2
in OSCC, we employed the lentivirus-delivered small interfering RNA (siRNA) technique to knock down
TPD52L2
expression in two OSCC cell lines, CAL27, and KB. Knockdown of
TPD52L2
by RNA interference markedly suppressed cell proliferation and colony formation. Cell cycle analysis showed that depletion of
TPD52L2
led to CAL27 cells arrest in the S phase. We found an excessive accumulation of cells in the sub-G1 phase, which can represent apoptotic cells.
TPD52L2
silencing also induced the cleavage of
PARP
. These results suggest that
TPD52L2
is involved in OSCC cell growth and serves as a potential therapeutic target in human OSCC.
...
PMID:Knockdown of tumor protein D52-like 2 induces cell growth inhibition and apoptosis in oral squamous cell carcinoma. 2690 48
Tumor protein D52-like 2
(
TPD52L2
) has been commonly described as a protein involved in tumorigenesis, according to its name. However, its pathological function remains under investigation. In the present study,
TPD52L2
was found to be widely expressed in several gastric cancer cell lines. An efficient knockdown of
TPD52L2
by a specific short hairpin RNA (shRNA) loaded in lentivirus resulted in a remarkable reduction in cell proliferation in both MGC80-3 and SGC-7901 cell lines with high
TPD52L2
expression, but a slight or little reduction in the proliferation of MKN-28 and AGS cells with low
TPD52L2
expression. Further analysis by flow cytometry revealed that the cell cycle was primarily blocked in the G0/G1 phase, especially in the sub-G1 phase by
TPD52L2
silencing, implying its possible roles in cell cycle control and apoptosis. Knockdown of
TPD52L2
caused a cleavage of
PARP
in MGC80-3 cells. Their study suggests that
TPD52L2
might promote gastric carcinogenesis, and could be a promising target with respect to developing new therapeutic strategies to treat gastric cancer.
...
PMID:Tumor protein D52-like 2 accelerates gastric cancer cell proliferation in vitro. 2919 59